1. Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system
- Author
-
Maya W. Haaker, Hedwig S. Kruitwagen, Arie B. Vaandrager, Martin Houweling, Louis C. Penning, Martijn R. Molenaar, Monique E. vanWolferen, Loes A. Oosterhoff, Bart Spee, and J. Bernd Helms
- Subjects
AICAR ,diacylglycerol O‐acyltransferase 1 inhibitor ,hepatic organoids ,perilipin 2 ,steatosis ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Background Hepatic lipidosis is increasing in incidence in the Western world, with cats being particularly sensitive. When cats stop eating and start utilizing their fat reserves, free fatty acids (FFAs) increase in blood, causing an accumulation of triacylglycerol (TAG) in the liver. Objective Identifying potential new drugs that can be used to treat hepatic lipidosis in cats using a feline hepatic organoid system. Animals Liver organoids obtained from 6 cats. Methods Eight different drugs were tested, and the 2 most promising were further studied using a quantitative TAG assay, lipid droplet staining, and qPCR. Results Both T863 (a diacylglycerol O‐acyltransferase 1 [DGAT1] inhibitor) and 5‐aminoimidazole‐4‐carboxamide 1‐β‐D‐ribofuranoside (AICAR; an adenosine monophosphate kinase activator) decreased TAG accumulation by 55% (P
- Published
- 2020
- Full Text
- View/download PDF